Trials / Completed
CompletedNCT00909688
Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses
Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To determine the safety, tolerability, and drug absorption profile of multiple IV doses of BLI 489 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BLI-489 | |
| DRUG | placebo |
Timeline
- Start date
- 2009-06-05
- Primary completion
- 2009-07-24
- Completion
- 2009-07-24
- First posted
- 2009-05-28
- Last updated
- 2018-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00909688. Inclusion in this directory is not an endorsement.